The #1 prescribed treatment for HD chorea1

Overnight switch at ~50% of the tetrabenazine dose2

Following overnight switch, reductions in TMC score were observed through 8 weeks
In an open-label, single-arm, multicenter study3

Reduction from baseline in TMC score, evaluated as an exploratory endpoint, observed at Weeks 1, 4, and 83

  • Dose adjustments were permitted after Week 1
  • At baseline, the median dose of tetrabenazine was 37.5 mg/day. The median doses of AUSTEDO were 18 mg/day (Week 1), 30 mg/day (Week 4), and 36 mg/day (Week 8)

TMC Score Following Overnight Switch to AUSTEDO3

ARC-HD: TMC score at weeks 1, 4, and 8, following overnight switch from tetrabenazine, 2.1 point change in TMC score from baseline at Week 8. ARC-HD: TMC score at weeks 1, 4, and 8, following overnight switch from tetrabenazine, 2.1 point change in TMC score from baseline at Week 8.

Deuterium helps maintain more consistent drug levels.1,2,4 Learn more about the PK profile of AUSTEDO.

Open-label, single-arm study design

The open-label, single-arm study was an 8-week study of patients (N=37) who switched overnight to AUSTEDO after ≥8 weeks of tetrabenazine. Patients were 41% female and 59% male. Average age was 52 years. Mean baseline TMC score was 12.5.3

Switching patients from tetrabenazine to AUSTEDO2

  • No washout required when switching patients with HD chorea from tetrabenazine
  • Patients may initiate AUSTEDO on the day following discontinuation of tetrabenazine
  • AUSTEDO is contraindicated in patients taking tetrabenazine

Recommended Initial Dose, After Switch From Tetrabenazine2

Chart showing recommended initial dose for AUSTEDO per current tetrabenazine dose. Chart showing recommended initial dose for AUSTEDO per current tetrabenazine dose.

After switching from tetrabenazine, the dose may be adjusted at weekly
intervals by 6 mg/day, following the dosing and titration schedule for AUSTEDO.2

HD, Huntington’s disease; PK, pharmacokinetic; TMC, total maximal chorea.

REFERENCES: 1. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 2. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 3. Frank S, Stamler D, Kayson E, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74(8):977-982. 4. Tung R. The development of deuterium-containing drugs. lnnov Pharm Technol. 2010;32(32):24-28.